What are the latest figures on the skyrizi market’s size and projected CAGR?
The skyrizi market size has XX (HCAGR) in recent years. It will grow from $XX million in 2024 to $XX million in 2025 at a compound annual growth rate (CAGR) of XX%. The growth in the historic period can be attributed to a rise in awareness of chronic inflammatory conditions, a rise in biosimilars, an increase in global healthcare access, an expansion of clinical indications, and a growth in long-term safety data.
The skyrizi market size is expected to see XX (FCAGR) in the next few years. It will grow to $XX million in 2029 at a compound annual growth rate (CAGR) of XX%. The growth in the forecast period can be attributed to growing adoption in psoriasis, increasing number of patients, growing geriatric population, increasing awareness and improved diagnosis, and increased consumption of processed foods. Major trends in the forecast period include technological innovations in biologics, a shift toward combination therapies, advancements in diagnostic technologies, a shift from oral to injectable treatments, and artificial intelligence (AI) for drug development.
Get Your Free Sample of The Global Skyrizi Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20266&type=smp
Which Market drivers have played a significant role in driving the skyrizi market?
The rising prevalence of psoriasis is expected to fuel the growth of the skyrizi market. Psoriasis refers to a chronic autoimmune condition that causes the rapid buildup of skin cells, leading to scaling on the skin’s surface. The rising prevalence of psoriasis is attributed to factors such as genetic predisposition, environmental triggers, increasing awareness and diagnosis rates, lifestyle changes, and the growing impact of stress and immune-related disorders on overall health. Skyrizi, a biologic therapy targeting interleukin-23 (IL-23), helps treat psoriasis by specifically blocking this cytokine, which plays a key role in the inflammatory process, thereby reducing skin inflammation, alleviating symptoms like redness and scaling, and improving overall skin clearance in patients with moderate to severe plaque psoriasis. For instance, in December 2022, according to the National Psoriasis Foundation (NPF), a US-based nonprofit organization, an estimated 8 million Americans and 125 million people worldwide (2-3% of the global population) have psoriasis. About 30% of those with psoriasis also develop psoriatic arthritis. Therefore, the rising prevalence of psoriasis drives the growth of skyrizi market.
What are the key segments within the skyrizi market?
The skyrizi market covered in this report is segmented –
1) By Indication: Plaque Psoriasis; Crohn’s Disease; Ulcerative Colitis
2) By Formulation: Pre-Filled Syringes; Vials
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/skyrizi-global-market-report
Which key players are shaping the skyrizi market?
Major companies operating in the skyrizi market are AbbVie Inc.
Which transformative trends will shape the skyrizi market landscape?
A key trend in the skyrizi market is focusing on the expansion of therapeutic indications such as ulcerative colitis to enhance treatment outcomes for autoimmune diseases. Skyrizi is approved for treating moderate-to-severe ulcerative colitis (UC), showing significant clinical improvements in patients who have not responded to other treatments. For instance, in July 2024, AbbVie Inc., a US-based biopharmaceutical company, received European Commission approval for Skyrizi (risankizumab) for treating adult patients with moderately to severely active ulcerative colitis (UC) who have not responded to, or are intolerant to, conventional or biologic therapies. The approval is based on positive results from the Phase 3 INSPIRE and COMMAND trials, particularly showing mucosal healing in patients without prior biologic or JAK inhibitor use. Skyrizi’s dosing includes a 1,200 mg induction followed by 180 mg or 360 mg maintenance doses every 8 weeks.
How do regional factors impact the skyrizi market, and which region is the largest contributor?
North America was the largest region in the skyrizi market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the skyrizi market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Skyrizi Market Report 2025 Offer?
The skyrizi market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Skyrizi refers to a prescription medication used to treat certain autoimmune conditions, including moderate to severe plaque psoriasis, active psoriatic arthritis, and Crohn’s disease, by reducing inflammation in the body. The mechanism of action of skyrizi (risankizumab-rzaa) involves selectively targeting and inhibiting interleukin-23 (IL-23), a protein that plays a key role in inflammatory and immune responses.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20266
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
